Samalizumab
Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R) . Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research[1].
Product Specifications
CAS Number
[1073059-33-2]
Product Name Alternative
ALXN 6000
UNSPSC
12352203
Target
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/samalizumab.html
Purity
99.95
Solubility
10 mM in DMSO
Smiles
[Samalizumab]
Molecular Weight
(144.84 kDa)
References & Citations
[1]Daruka Mahadevan, et al. Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. J Immunother Cancer. 2019 Aug 23;7 (1) :227.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
